The PARP Inhibitors: Down But Not Out

Jane de Lartigue, PhD
Published: Tuesday, Jul 31, 2012
PARP1 Protein structure

Two views of the protein structure of a PARP1 inhibitor complex.

Poly(ADP-ribose) polymerase (PARP) inhibitors, particularly Sanofi’s iniparib and AstraZeneca’s olaparib, have elicited both great excitement and significant disappointment in equal measure in recent years as researchers pursue these agents in the treatment of several types of cancer with poor prognoses.

What Are PARPs? PARPs are a family of enzymes implicated in a host of key cellular processes, including chromosome stability, regulation of apoptosis, cell division, and transcriptional regulation and differentiation. A particularly important role of PARPs is in repairing DNA damage that results from everyday environmental stresses and DNA replication errors.

Major DNA Repair Pathways

PARP inhibition leads to apoptosis

PARP plays a central role in DNA repair, and researchers theorize that inhibiting PARP

would result in cancer cell death.

Inhibiting PARP to Treat Cancer: Synthetic Lethality and Beyond

The potential anticancer activity of PARP inhibitors was first elucidated in 2005. Currently, PARP inhibitors are designed to target the catalytic site of PARP1 and inhibit PARP1 by greater than 90%. They are thought to function in the treatment of cancer by exploiting the concept of synthetic lethality.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Articles
Blogs
Conference Coverage
OncLive TV
Peer Exchange
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
 
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.
 
x